Cellebrite DI Ltd. Form 6-K Filing Summary

This Form 6-K filing from Cellebrite DI Ltd. addresses inquiries regarding dilution figures disclosed in the company's 2026 Annual General Meeting proxy statement. As of August 1, 2026, the company reported 251,341,060 ordinary shares outstanding. The total number of ordinary shares subject to awards under the 2021 Share Incentive Plan was 12,917,566, with an additional 10,418,086 shares available for future grants. Notably, 3,500,000 shares were removed from the SIP reservation following a Board of Directors' approval on July 29, 2026, as part of an ongoing review of the equity compensation program. Furthermore, 2,218,509 ordinary shares were available under the Employee Share Purchase Plan. The aggregate number of ordinary shares reserved for issuance under equity compensation plans was 25,554,161. Based on a fully diluted share count of 276,895,221 ordinary shares as of August 1, 2026, the potential dilution was approximately 9.2%. This report is incorporated by reference into the Company’s registration statements on Form S-8 and Form F-3.